Thomas J. Herzog

20.6k total citations · 5 hit papers
334 papers, 13.3k citations indexed

About

Thomas J. Herzog is a scholar working on Reproductive Medicine, Obstetrics and Gynecology and Surgery. According to data from OpenAlex, Thomas J. Herzog has authored 334 papers receiving a total of 13.3k indexed citations (citations by other indexed papers that have themselves been cited), including 190 papers in Reproductive Medicine, 140 papers in Obstetrics and Gynecology and 107 papers in Surgery. Recurrent topics in Thomas J. Herzog's work include Ovarian cancer diagnosis and treatment (173 papers), Endometrial and Cervical Cancer Treatments (119 papers) and Intraperitoneal and Appendiceal Malignancies (58 papers). Thomas J. Herzog is often cited by papers focused on Ovarian cancer diagnosis and treatment (173 papers), Endometrial and Cervical Cancer Treatments (119 papers) and Intraperitoneal and Appendiceal Malignancies (58 papers). Thomas J. Herzog collaborates with scholars based in United States, United Kingdom and Germany. Thomas J. Herzog's co-authors include Jason D. Wright, Sharyn N. Lewin, William M. Burke, Alfred I. Neugut, Dawn L. Hershman, Bradley J. Monk, David G. Mutch, Yu‐Shiang Lu, Robert L. Coleman and Janet S. Rader and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and JAMA.

In The Last Decade

Thomas J. Herzog

325 papers receiving 13.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nationwide Trends in the Performance of Inpatient Hysterectomy in the United States

2013 545 citations Jason D. Wright, Thomas J. Herzog et al. Obstetrics and Gynecology profile →
Latest research and treatment of advanced-stage epithelial ovarian cancer

2013 408 citations Robert L. Coleman, Bradley J. Monk et al. profile →
Robotically Assisted vs Laparoscopic Hysterectomy Among Women With Benign Gynecologic Disease

2013 407 citations Jason D. Wright, Cande V. Ananth et al. profile →
Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

2017 406 citations Robert L. Coleman, Thomas J. Herzog et al. profile →
Endometrial cancer: A review and current management strategies: Part II

2014 354 citations William M. Burke, James W. Orr et al. Gynecologic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas J. Herzog United States	64	6.2k	6.1k	3.3k	3.2k	1.8k	334	13.3k
Pierluigi Benedetti Panici Italy	63	6.6k 1.1×	6.7k 1.1×	3.9k 1.2×	3.6k 1.1×	2.8k 1.6×	566	16.0k
John K. Chan United States	60	5.1k 0.8×	3.7k 0.6×	2.9k 0.9×	4.1k 1.3×	1.9k 1.0×	277	11.9k
Jonathan S. Berek United States	67	8.1k 1.3×	7.4k 1.2×	4.7k 1.4×	4.3k 1.3×	1.9k 1.0×	297	16.6k
Peter G. Rose United States	54	5.8k 0.9×	6.5k 1.1×	4.1k 1.3×	3.2k 1.0×	1.6k 0.9×	274	12.2k
Richard R. Barakat United States	70	10.0k 1.6×	9.6k 1.6×	5.3k 1.6×	3.5k 1.1×	1.5k 0.8×	286	18.0k
William A. Cliby United States	64	6.8k 1.1×	5.2k 0.8×	4.2k 1.3×	3.5k 1.1×	3.8k 2.1×	288	14.3k
David E. Cohn United States	58	4.3k 0.7×	5.0k 0.8×	2.0k 0.6×	2.9k 0.9×	2.9k 1.6×	377	12.2k
Barbara A. Goff United States	57	5.4k 0.9×	3.4k 0.5×	2.6k 0.8×	2.4k 0.7×	1.4k 0.8×	231	10.2k
Robert E. Bristow United States	65	10.4k 1.7×	6.3k 1.0×	6.5k 2.0×	2.9k 0.9×	1.6k 0.9×	313	15.2k
Neville F. Hacker Australia	59	4.4k 0.7×	3.9k 0.6×	3.8k 1.2×	2.6k 0.8×	2.4k 1.3×	246	11.4k

Countries citing papers authored by Thomas J. Herzog

Since Specialization

Citations

This map shows the geographic impact of Thomas J. Herzog's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas J. Herzog with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas J. Herzog more than expected).

Fields of papers citing papers by Thomas J. Herzog

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas J. Herzog. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas J. Herzog. The network helps show where Thomas J. Herzog may publish in the future.

Co-authorship network of co-authors of Thomas J. Herzog

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas J. Herzog. A scholar is included among the top collaborators of Thomas J. Herzog based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas J. Herzog. Thomas J. Herzog is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Moore, Kathleen N., Ana Oaknin, Isabelle Ray‐Coquard, et al.. (2024). GOG-3084: A phase II trial of ADP-A2M4CD8 TCR-T cell therapy, alone or in combination with nivolumab, among patients with recurrent ovarian cancers. Gynecologic Oncology. 190. S281–S282. 1 indexed citations

Gaillard, Stéphanie, Sachin Kumar Deshmukh, Utthara Nayar, et al.. (2024). Characterization of ESR1 mutations in endometrial and ovarian cancers.. Journal of Clinical Oncology. 42(16_suppl). 5598–5598. 1 indexed citations

Moore, Kathleen N., Ana Oaknin, Isabelle Ray‐Coquard, et al.. (2023). #24 A phase 2 study (GOG-3084) OF ADP-A2M4CD8 TCR T-cell therapy, alone or in combination with nivolumab, in patients with recurrent ovarian cancers. A407.2–A408. 1 indexed citations

Mirza, Mansoor Raza, David M. O’Malley, Philipp Harter, et al.. (2022). 2022-RA-439-ESGO Up-next (ENGOT-Ov71-NSGO-CTU/GOG-3049): a study of upitifamab rilsodotin (UpRi), a napi2b-directed antibody drug conjugate (ADC) in platinum-sensitive recurrent ovarian cancer. International Journal of Gynecological Cancer. 32. A234–A234. 1 indexed citations

Santin, Alessandro D., Ignace Vergote, Antonio González-Martı́n, et al.. (2022). Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study. International Journal of Gynecological Cancer. 33(4). 1–9. 28 indexed citations

Hughes, Brittany N., Thomas J. Herzog, Jubilee Brown, & R. Wendel Naumann. (2021). Opportunistic Salpingectomy at Time of Nongynecologic Elective Procedures Could Reduce Ovarian Cancer–Related Costs and Mortality. Journal of Gynecologic Surgery. 38(1). 43–48. 7 indexed citations

Naumann, R. Wendel, et al.. (2021). The impact of opportunistic salpingectomy on ovarian cancer mortality and healthcare costs: a call for universal insurance coverage. American Journal of Obstetrics and Gynecology. 225(4). 397.e1–397.e6. 19 indexed citations

Arend, Rebecca C., et al.. (2018). Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm. The Oncologist. 23(12). 1533–1545. 19 indexed citations

Tewari, Devansu, James Java, Ritu Salani, et al.. (2015). Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer. Obstetrical & Gynecological Survey. 70(8). 505–506. 2 indexed citations

10.

Jackson, Amanda, Sara Davenport, Thomas J. Herzog, & Robert L. Coleman. (2015). Targeting angiogenesis: Vascular endothelial growth factor and related signaling pathways. Translational Cancer Research. 4(1). 70–83. 5 indexed citations

11.

Rutherford, Thomas, James W. Orr, Edward C. Grendys, et al.. (2014). A Prospective Study Evaluating the Clinical Relevance of a Chemoresponse Assay for Treatment of Patients With Persistent or Recurrent Ovarian Cancer. Obstetrical & Gynecological Survey. 69(5). 259–260. 1 indexed citations

12.

Herzog, Thomas J., Giovanni Scambia, Byoung‐Gie Kim, et al.. (2013). A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. Gynecologic Oncology. 130(1). 25–30. 69 indexed citations

13.

Ananth, Cande V., Sharyn N. Lewin, William M. Burke, et al.. (2013). Utilization and Safety of Sodium Hyaluronate-Carboxymethylcellulose Adhesion Barrier. Diseases of the Colon & Rectum. 56(10). 1174–1184. 10 indexed citations

14.

Schiavone, Maria B., Thomas J. Herzog, Cande V. Ananth, et al.. (2012). Feasibility and economic impact of same-day discharge for women who undergo laparoscopic hysterectomy. American Journal of Obstetrics and Gynecology. 207(5). 382.e1–382.e9. 92 indexed citations

15.

Wright, Jason D., Patricia Devine, Monjri Shah, et al.. (2010). Morbidity and Mortality of Peripartum Hysterectomy. Obstetrics and Gynecology. 115(6). 1187–1193. 108 indexed citations

16.

Herzog, Thomas J., Thomas C. Krivak, Amanda N. Fader, & Robert L. Coleman. (2010). Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer. American Journal of Obstetrics and Gynecology. 203(1). 68.e1–68.e6. 39 indexed citations

17.

Wright, Jason D., et al.. (2009). Safety of Ovarian Preservation in Premenopausal Women With Endometrial Cancer. Journal of Clinical Oncology. 27(8). 1214–1219. 105 indexed citations

18.

Bansal, Nisha, Thomas J. Herzog, Venkatraman Seshan, et al.. (2008). Uterine Carcinosarcomas and Grade 3 Endometrioid Cancers. Obstetrics and Gynecology. 112(1). 64–70. 82 indexed citations

19.

Bansal, Nisha, Jason D. Wright, Carmel J. Cohen, & Thomas J. Herzog. (2008). Natural history of established low grade cervical intraepithelial (CIN 1) lesions.. PubMed. 28(3B). 1763–6. 71 indexed citations

20.

Whitcomb, Bradford P., David G. Mutch, Thomas J. Herzog, et al.. (2003). Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma.. PubMed. 9(6). 2277–87. 86 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact